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criteria, and exclusion criteria avail-
able from the author). The quality of
these studies is quite variable, and
quality is certainly more important
than quantity. Most trials of the newer
agents were designed and funded by
industry. In general, ciprofloxacin and
levofloxacin have been studied in
patient populations with more severe
illnesses, including nosocomial infec-
tions, than the newer quinolones.
With the exception of a single moxi-
floxacin trial (8), the trials of the
newer quinolones have enrolled
patients with predominantly mild or
moderate community-acquired infec-
tions and low overall mortality rates.
Scheld provides a table that lists
case reports of clinical failures of lev-
ofloxacin for the treatment of pneu-
mococcal infections. Some cases were
associated with primary or secondary
levofloxacin resistance. These case
reports should not be surprising, since
CAP trials regularly identify clinical
failures regardless of the therapy cho-
sen. The rate of clinical failure is best
determined by data from prospective
trials rather than case reports. Both
levofloxacin and moxifloxacin have
performed well in patients with severe
pneumococcal infections, on the basis
of the rates of therapeutic success and
death (8–10).
Scheld’s choice of ciprofloxacin as
a component of combination therapy
for suspected P. aeruginosa infections
can be affirmed. Ciprofloxacin has
pharmacodynamic potency against P.
aeruginosa, a track record of safety in
large populations, and a large pub-
lished literature. Ciprofloxacin has
demonstrated efficacy in patient pop-
ulations with severe illnesses, includ-
ing nosocomial infections. 
Antimicrobial drug therapy deci-
sion-making for patients with CAP
and other respiratory tract infections
is much more complex. Individual
patient factors should be considered,
including the severity of illness,
coexisting illnesses, risk factors for
drug-resistant  S. pneumoniae, and
risk factors for specific adverse
effects. A respiratory quinolone will
be an appropriate choice for some
patients with CAP. Among the respi-
ratory quinolones, a wholesale switch
from levofloxacin to moxifloxacin,
on the basis of pneumococcal poten-
cy alone, would be premature.
Clinicians should use newer
quinolones cautiously until their safe-
ty has been established in large
patient populations.
Richard Frothingham*
*Veterans Affairs Medical Center and Duke
University Medical Center, Durham, North
Carolina, USA
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Vancomycin-
resistant
Enterococcus 
faecalis in Serbia
To the Editor: First isolated in
France (1), vancomycin-resistant
enterococci (VRE) have become
pathogens of major importance, par-
ticularly in the United States (2).
Infections due to VRE are still
uncommon in most European coun-
tries (3). We report the first isolation
of high-level vancomycin-resistant
Enterococcus faecalis in Serbia. 
A 55-year-old woman was admit-
ted to the Clinic for Cardiovascular
Diseases, Belgrade, on April 1, 2002,
for aortobifemoral bypass surgery.
Three weeks after she was admitted to
the hospital, an infection developed in
the surgical wound and treatment with
trimethoprim-sulfamethoxazole
(160/800 mg q 12 h) was empirically
introduced. Bacteriologic analysis of
the wound swab sample showed a
methicillin-resistant strain of
Staphylococcus aureus, a multiresis-
tant strain of Acinetobacter sp., a com-
monly susceptible strain of
Enterococcus sp., and a VRE strain.
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According to the results of susceptibil-
ity testing, imipenem (1 g q 6 h) was
added to the patient’s treatment proto-
col. VRE were not isolated from sub-
sequent wound samples or any other
sample submitted for microbiologic
analysis. The patient was discharged at
the end of the 14-day treatment period. 
The isolate was identified as E. fae-
calis by biochemical characterization,
as recommended by Facklam and
Collins (4) and confirmed by API 20
Strep (bioMérieux, Marcy-l’Etoile,
France). Susceptibility testing, per-
formed by the disk diffusion method,
showed that the isolate was resistant to
vancomycin, teicoplanin, gentamicin,
streptomycin, tetracycline, and
ciprofloxacin, while susceptible to
ampicillin, amoxicillin, amoxicillin
and clavulanic acid, and imipenem.
Resistance to vancomycin, teico-
planin, gentamicin, and streptomycin
was confirmed by the broth dilution
method, according to the National
Committee for Clinical Laboratory
Standards (NCCLS) recommendations
(5). The obtained MICs were 256
µg/mL for vancomycin, 64 µg/mL for
teicoplanin, >4,000 µg/mL for gen-
tamicin, and >2,000 µg/mL for strep-
tomycin. This phenotype, with high-
level resistance to vancomycin and
teicoplanin, is typical for the vanA
genotype (2). The strain was subse-
quently genotyped by pulsed-field gel
electrophoresis, using previously
described methods (6). The presence
of the vanA gene was confirmed by
polymerase chain reaction assay,
according to a previously described
procedure (7). E. faecium EF228 was
used as the positive control.
The enterococci are among the
most frequent causes of nosocomial
infections, particularly in intensive
care units, and present a major thera-
peutic challenge (2). While the emer-
gence of VRE strains in the United
States is probably associated with
extensive use of vancomycin, the
occurrence of VRE in Europe is pos-
sibly due to application of avoparcin
(glycopeptide analog) as a growth
promoter in animal husbandry (3).
However, avoparcin has not been used
in Serbia, and vancomycin application
has been restricted to hospitalized
patients and quite limited due to its
high cost. Thus, emergence of VRE
strains in Serbia has not been likely. 
The origin of this VRE isolate is
unknown: the strain may have been
imported or may have originated from
the hospital environment. The first
prospective pan-European VRE sur-
veillance study (January–April 1997)
showed VanA-VRE strains in only
eight European countries, with iso-
lates numbering from one to four per
country (3). No epidemiologic rela-
tions were established among the
VanA isolates, and only 2 out of 18
isolates (11%) were identified as E.
faecalis (3). Since our patient-case
had no history of travel outside Serbia,
we assumed that the VRE isolate orig-
inated from the hospital environment.
However, a study investigating the
occurrence of VRE strains in
Belgrade, the capital of Serbia, detect-
ed no such isolates in five different
hospitals (8). Although the study did
not analyze samples from the Clinic
for Cardiovascular Diseases, it did
include samples from the Clinic for
General Surgery, which is located
within the same building. The suscep-
tibility of 191 isolates of enterococci
to vancomycin was tested by agar
dilution method according to NCCLS
recommendations. Of the 191 isolates,
159 were classified as susceptible and
32 as intermediately susceptible. 
This report of the first isolation of
VRE in Serbia, as well as the previ-
ously shown presence of enterococci
displaying intermediary susceptibility
to vancomycin, provides the rationale
for future active screening for VRE in
hospital environments in the region. 
Branka Stošovic,* Srdjan
Stepanovic,† Susan Donabedian,‡
Tanja Tošic,* and Milica Jovanovic* 
*Institute of Infectious and Tropical
Diseases “Dr Kosta Todorovic,” Belgrade,
Serbia; †University of Belgrade School of
Medicine, Belgrade, Serbia; and ‡William
Beaumont Hospital, Royal Oak, Michigan,
USA
References
1. Leclercq R, Derlot E, Duval J, Courvalin P.
Plasmid-mediated resistance to van-
comycin and teicoplanin in Enterococcus
faecium. N Engl J Med 1988;319:157–61. 
2. Cetinkaya Y, Falk P, Mayhall CG.
Vancomycin-resistant enterococci. Clin
Microbiol Rev 2000;13:686–707.
3. Schouten MA, Hoogkamp-Korstanje JA,
Meis JF, Voss A. Prevalence of van-
comycin-resistant enterococci in Europe.
Eur J Clin Microbiol Infect Dis
2000;19:816–22.
4. Facklam RR, Collins MD. Identification of
Enterococcus species isolated from human
infections by a conventional test scheme. J
Clin Microbiol 1989;27:731–4. 
5. National Committee for Clinical
Laboratory Standards. Methods for dilution
antimicrobial susceptibility tests for bacte-
ria that grow aerobically. Approved stan-
dard M7-A4. Wayne (PA): National
Committee for Clinical Laboratory
Standards; 1997.
6. Donabedian S, Chow JW, Shlaes DM,
Green M, Zervos MJ. DNA hybridization
and contour-clamped homogeneous electric
field electrophoresis for identification of
enterococci to the species level. J Clin
Microbiol 1995;33:141–5.
7. Clark NC, Cooksey RC, Hill BC, Swenson
JM, Tenover FC. Characterization of gly-
copeptide-resistant enterococci from U.S.
hospitals. Antimicrob Agents Chemother
1993;37:2311–7.
8. Dakic I, Vukovic D, Stepanovic S, Kalezic
I, Švabic-Vlahovic M. Enterococci isolated
in Belgrade hospitals: the resistance to van-
comycin. In: Abstract book of the 9th
International Congress on Infectious
Diseases, Buenos Aires, Argentina, 2000
April 10–13; p. 213.
Address for correspondence: Srdjan
Stepanovic, Institute of Microbiology and
Immunology, University of Belgrade School of
Medicine, Dr Subotica 1, 11000 Belgrade,
Serbia; fax: +381-11-656950; email: stepan@
afrodita.rcub.bg.ac.yu
158 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 1, January 2004